JP4060892B2 - タンパク質のｉｎ ｖｉｔｒｏディスプレイ及び進化のための選択粒子としてのリボソーム複合体 - Google Patents
タンパク質のｉｎ ｖｉｔｒｏディスプレイ及び進化のための選択粒子としてのリボソーム複合体 Download PDFInfo
- Publication number
- JP4060892B2 JP4060892B2 JP50038699A JP50038699A JP4060892B2 JP 4060892 B2 JP4060892 B2 JP 4060892B2 JP 50038699 A JP50038699 A JP 50038699A JP 50038699 A JP50038699 A JP 50038699A JP 4060892 B2 JP4060892 B2 JP 4060892B2
- Authority
- JP
- Japan
- Prior art keywords
- mrna
- protein
- dna
- peptide
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 85
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 69
- 238000000338 in vitro Methods 0.000 title claims abstract description 28
- 239000002245 particle Substances 0.000 title claims description 17
- 108020004999 messenger RNA Proteins 0.000 claims abstract description 124
- 238000000034 method Methods 0.000 claims abstract description 119
- 238000011084 recovery Methods 0.000 claims abstract description 62
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 53
- 230000027455 binding Effects 0.000 claims abstract description 50
- 238000009739 binding Methods 0.000 claims abstract description 50
- 238000013519 translation Methods 0.000 claims abstract description 39
- 239000000427 antigen Substances 0.000 claims abstract description 24
- 102000036639 antigens Human genes 0.000 claims abstract description 24
- 108091007433 antigens Proteins 0.000 claims abstract description 24
- 230000002068 genetic effect Effects 0.000 claims abstract description 24
- 238000013518 transcription Methods 0.000 claims abstract description 24
- 230000035897 transcription Effects 0.000 claims abstract description 23
- 210000003705 ribosome Anatomy 0.000 claims abstract description 20
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 17
- 239000003446 ligand Substances 0.000 claims abstract description 14
- 238000010839 reverse transcription Methods 0.000 claims abstract description 10
- 238000003752 polymerase chain reaction Methods 0.000 claims abstract 5
- 239000011324 bead Substances 0.000 claims description 55
- 239000002299 complementary DNA Substances 0.000 claims description 42
- 239000012634 fragment Substances 0.000 claims description 29
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 26
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 26
- 238000002702 ribosome display Methods 0.000 claims description 25
- 108020004705 Codon Proteins 0.000 claims description 21
- 230000035772 mutation Effects 0.000 claims description 18
- 239000000126 substance Substances 0.000 claims description 11
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 210000001995 reticulocyte Anatomy 0.000 claims description 9
- 241000588724 Escherichia coli Species 0.000 claims description 7
- 241000894006 Bacteria Species 0.000 claims description 6
- 239000006166 lysate Substances 0.000 claims description 6
- 230000009466 transformation Effects 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 5
- 238000011830 transgenic mouse model Methods 0.000 claims description 5
- 210000004671 cell-free system Anatomy 0.000 claims description 4
- 210000004698 lymphocyte Anatomy 0.000 claims description 4
- 108700019146 Transgenes Proteins 0.000 claims description 3
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 108020004414 DNA Proteins 0.000 claims 25
- 239000011246 composite particle Substances 0.000 claims 17
- 238000012804 iterative process Methods 0.000 claims 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 239000002131 composite material Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 238000013507 mapping Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 abstract description 12
- 238000010494 dissociation reaction Methods 0.000 abstract description 5
- 230000005593 dissociations Effects 0.000 abstract description 5
- 238000003757 reverse transcription PCR Methods 0.000 description 52
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 38
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 30
- 230000014616 translation Effects 0.000 description 29
- 210000002729 polyribosome Anatomy 0.000 description 22
- 229960003387 progesterone Drugs 0.000 description 19
- 239000000186 progesterone Substances 0.000 description 19
- 229960003604 testosterone Drugs 0.000 description 16
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 15
- 238000011144 upstream manufacturing Methods 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 239000000499 gel Substances 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 239000003550 marker Substances 0.000 description 8
- 150000003431 steroids Chemical class 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 108010032595 Antibody Binding Sites Proteins 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 238000005457 optimization Methods 0.000 description 5
- 238000002823 phage display Methods 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 239000003418 antiprogestin Substances 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 238000000326 densiometry Methods 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 238000010841 mRNA extraction Methods 0.000 description 3
- 239000011654 magnesium acetate Substances 0.000 description 3
- 235000011285 magnesium acetate Nutrition 0.000 description 3
- 229940069446 magnesium acetate Drugs 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 230000003623 progesteronic effect Effects 0.000 description 3
- 238000002818 protein evolution Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 210000004988 splenocyte Anatomy 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- JBBNFGYRYNBDIH-DBGGZKJISA-N 11alpha-hydroxyprogesterone hemisuccinate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)C[C@H]2OC(=O)CCC(O)=O JBBNFGYRYNBDIH-DBGGZKJISA-N 0.000 description 2
- PPELYUTTZHLIAZ-CDUDAXDSSA-N 2-[(e)-[(8s,9s,10r,13s,14s,17s)-17-acetyl-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-ylidene]amino]oxyacetic acid Chemical compound C1CC2=C\C(=N\OCC(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 PPELYUTTZHLIAZ-CDUDAXDSSA-N 0.000 description 2
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 2
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 108091060545 Nonsense suppressor Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 102000006010 Protein Disulfide-Isomerase Human genes 0.000 description 2
- 238000003314 affinity selection Methods 0.000 description 2
- 230000010310 bacterial transformation Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000006249 magnetic particle Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 231100000299 mutagenicity Toxicity 0.000 description 2
- 230000007886 mutagenicity Effects 0.000 description 2
- 108020003519 protein disulfide isomerase Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 239000013076 target substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 101100177262 Casuarina glauca HBII gene Proteins 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 238000012270 DNA recombination Methods 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 108091032917 Transfer-messenger RNA Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 102000025171 antigen binding proteins Human genes 0.000 description 1
- 108091000831 antigen binding proteins Proteins 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 238000012926 crystallographic analysis Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 108010007425 oligomycin sensitivity conferring protein Proteins 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 101150059999 pro gene Proteins 0.000 description 1
- 108010066545 progesterone-11-bovine serum albumin Proteins 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1041—Ribosome/Polysome display, e.g. SPERT, ARM
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9710829.4A GB9710829D0 (en) | 1997-05-28 | 1997-05-28 | Selection particles for in vitro display and evolution of antibody combining sites |
| GB9710829.4 | 1997-05-28 | ||
| GB9724850.4 | 1997-11-26 | ||
| GBGB9724850.4A GB9724850D0 (en) | 1997-11-26 | 1997-11-26 | Selection particles for in vitro display and evolution of antibody combining sites |
| GB9804195.7 | 1998-02-28 | ||
| GBGB9804195.7A GB9804195D0 (en) | 1998-02-28 | 1998-02-28 | Selection particles for in vitro display and evolution of antibody combining sites |
| PCT/GB1998/001564 WO1998054312A1 (en) | 1997-05-28 | 1998-05-28 | Ribosome complexes as selection particles for in vitro display and evolution of proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002500514A JP2002500514A (ja) | 2002-01-08 |
| JP2002500514A5 JP2002500514A5 (enExample) | 2005-12-08 |
| JP4060892B2 true JP4060892B2 (ja) | 2008-03-12 |
Family
ID=27268863
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP50038699A Expired - Fee Related JP4060892B2 (ja) | 1997-05-28 | 1998-05-28 | タンパク質のｉｎ ｖｉｔｒｏディスプレイ及び進化のための選択粒子としてのリボソーム複合体 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6620587B1 (enExample) |
| EP (1) | EP0985032B2 (enExample) |
| JP (1) | JP4060892B2 (enExample) |
| AT (1) | ATE250668T1 (enExample) |
| CA (1) | CA2291721C (enExample) |
| DE (1) | DE69818458T3 (enExample) |
| DK (1) | DK0985032T4 (enExample) |
| ES (1) | ES2209145T5 (enExample) |
| PT (1) | PT985032E (enExample) |
| WO (1) | WO1998054312A1 (enExample) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4854999A (en) * | 1998-07-02 | 2000-01-24 | Invitro Diagnostics, Inc. | Methods, compositions and apparatus for making nucleic acid molecules having a selected affinity to a target molecule |
| DE19932688B4 (de) | 1999-07-13 | 2009-10-08 | Scil Proteins Gmbh | Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen |
| GB9917027D0 (en) * | 1999-07-20 | 1999-09-22 | Affibody Technology Sweeden Ab | In vitro selection and optional identification of polypeptides using solid support carriers |
| EP1276900A2 (en) | 2000-01-11 | 2003-01-22 | Maxygen, Inc. | Integrated systems and methods for diversity generation and screening |
| CA2402452A1 (en) | 2000-03-31 | 2001-10-11 | Cambridge Antibody Technology Limited | Improvements to ribosome display |
| EP1652919A1 (en) * | 2000-03-31 | 2006-05-03 | Cambridge Antibody Technology LTD | Improvements to ribosome display |
| US7129326B2 (en) | 2000-04-14 | 2006-10-31 | Genencor International, Inc. | Methods for selective targeting |
| US20020098524A1 (en) | 2000-04-14 | 2002-07-25 | Murray Christopher J. | Methods for selective targeting |
| EP1372721A4 (en) | 2001-03-07 | 2008-04-02 | Childrens Medical Center | METHOD FOR SCREENING PEPTIDE DISPLAY LIBRARIES WITH A MINIMUM DISPLAY |
| EP1401850A1 (en) * | 2001-06-20 | 2004-03-31 | Nuevolution A/S | Nucleoside derivatives for library preparation |
| US20060234231A1 (en) * | 2001-06-20 | 2006-10-19 | Nuevolution A/S | Microarrays displaying encoded molecules |
| DE10145226A1 (de) * | 2001-09-13 | 2003-04-10 | Lifebits Ag | Herstellung von trägergebundenen Molekülen |
| DE10147074A1 (de) * | 2001-09-25 | 2003-05-08 | Beru Ag | Verfahren zum Betreiben einer aus mehreren Heizelementen bestehenden mehrstufigen elektrischen Heizung |
| DE20200926U1 (de) * | 2002-01-23 | 2002-04-18 | Hegenscheidt-MFD GmbH & Co. KG, 41812 Erkelenz | Festwalzgerät einer Festwalzmaschine für Kurbelwellen |
| EP1490384A2 (en) * | 2002-03-15 | 2004-12-29 | Nuevolution A/S | A building block forming a c-c bond upon reaction |
| WO2003078626A2 (en) * | 2002-03-15 | 2003-09-25 | Nuevolution A/S | A building block capable of transferring a functional entity |
| CN101006177B (zh) | 2002-03-15 | 2011-10-12 | 纽韦卢森公司 | 改善的用于合成模制分子的方法 |
| WO2003078446A2 (en) * | 2002-03-15 | 2003-09-25 | Nuevolution A/S | A building block forming a c-c or a c-hetero atom bond upon reaction |
| AU2003247266A1 (en) * | 2002-08-01 | 2004-02-23 | Nuevolution A/S | Multi-step synthesis of templated molecules |
| US7842476B2 (en) * | 2002-09-06 | 2010-11-30 | Isogenica Limited | In vitro peptide expression library |
| CN106337046B (zh) | 2002-10-30 | 2021-03-23 | 纽韦卢森公司 | 合成双功能复合物的方法 |
| WO2004048399A2 (en) | 2002-11-25 | 2004-06-10 | Genencor International, Inc. | Skin or hair binding peptides |
| ATE450609T1 (de) * | 2002-12-19 | 2009-12-15 | Nuevolution As | Durch quasizufallsstrukturen und funktionen geführte synthesemethode |
| WO2004074501A2 (en) * | 2003-02-21 | 2004-09-02 | Nuevolution A/S | A method for obtaining structural information about an encoded molecule |
| US20070026397A1 (en) | 2003-02-21 | 2007-02-01 | Nuevolution A/S | Method for producing second-generation library |
| DE602004021094D1 (de) * | 2003-03-19 | 2009-06-25 | Discerna Ltd | Gewinnung von dna |
| US7915201B2 (en) * | 2003-03-20 | 2011-03-29 | Nuevolution A/S | Ligational encoding of small molecules |
| DE10324447A1 (de) | 2003-05-28 | 2004-12-30 | Scil Proteins Gmbh | Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin |
| GB0316314D0 (en) * | 2003-07-12 | 2003-08-13 | Univ Belfast | Method |
| ATE447626T1 (de) | 2003-09-18 | 2009-11-15 | Nuevolution As | Methode zur gewinnung struktureller informationen kodierter moleküle und zur selektion von verbindungen |
| US20090239211A1 (en) * | 2004-02-17 | 2009-09-24 | Nuevolution A/S | Method For Enrichment Involving Elimination By Mismatch Hybridisation |
| DE602005017370D1 (de) * | 2004-03-22 | 2009-12-10 | Nuevolution As | Ligationscodierung unter verwendung von oligonukleotidbausteinen |
| US20050250112A1 (en) * | 2004-05-07 | 2005-11-10 | Padmabandu Gothami A | Nucleic acids, compositions, methods, and kits for detecting mycoplasma and acholeplasma species |
| US9006393B1 (en) | 2004-08-26 | 2015-04-14 | Patricia L. Clark | Molecular constructs and uses thereof in ribosomal translational events |
| DE102004049479A1 (de) | 2004-10-11 | 2006-04-13 | Scil Proteins Gmbh | Proteinkonjugate zur Verwendung in Therapie, Diagnose und Chromatographie |
| LT3018206T (lt) | 2005-12-01 | 2021-12-10 | Nuevolution A/S | Fermentiniai kodavimo būdai, skirti didelių bibliotekų efektyviai sintezei |
| GB0605584D0 (en) | 2006-03-20 | 2006-04-26 | Olink Ab | Method for analyte detection using proximity probes |
| US7777002B2 (en) * | 2006-06-29 | 2010-08-17 | The Invention Science Fund I, Llc | Methods for arbitrary peptide synthesis |
| US7910695B2 (en) | 2006-06-29 | 2011-03-22 | The Invention Science Fund I, Llc | Methods for arbitrary peptide synthesis |
| US7879975B2 (en) * | 2006-06-29 | 2011-02-01 | The Invention Science Fund I, Llc | Methods for arbitrary peptide synthesis |
| US7923533B2 (en) * | 2006-06-29 | 2011-04-12 | The Invention Science Fund I, Llc | Methods for arbitrary peptide synthesis |
| US7816101B2 (en) * | 2006-06-29 | 2010-10-19 | The Invention Science Fund I, Llc | Apparatus for arbitrary peptide synthesis |
| EP1925664A1 (en) | 2006-11-15 | 2008-05-28 | Scil proteins GmbH | Artificial binding proteins based on a modified alpha helical region of ubiquitin |
| US8865179B2 (en) * | 2008-01-26 | 2014-10-21 | Swey-Shen Alexchen | Aptameric IgE peptides in a protein scaffold as an allergy vaccine |
| KR20110036638A (ko) * | 2008-07-25 | 2011-04-07 | 리차드 더블유. 와그너 | 단백질 스크리닝 방법 |
| CN102227638B (zh) * | 2008-09-30 | 2015-05-20 | Abbvie公司 | Rna展示的改良方法 |
| BR112012014194A2 (pt) | 2009-12-14 | 2017-01-10 | Scil Proteins Gmbh | um método para identificar proteínas ubiquitinas modificadas hetero-multiméricas com capacidade de ligação a ligandos |
| EP2546342A4 (en) | 2010-03-11 | 2013-12-04 | Riken | METHOD FOR SELECTION OF A POLYPEPTIDE SEQUENCE, METAL OXIDE OR SILICON WITH A BONDING SPEPTIDE AND USE THEREOF |
| GB201004292D0 (en) | 2010-03-15 | 2010-04-28 | Olink Ab | Assay for localised detection of analytes |
| CA2832672A1 (en) | 2010-04-16 | 2011-10-20 | Nuevolution A/S | Bi-functional complexes and methods for making and using such complexes |
| GB201011971D0 (en) | 2010-07-15 | 2010-09-01 | Olink Ab | Methods and product |
| US10669569B2 (en) | 2010-10-15 | 2020-06-02 | Navinci Diagnostics Ab | Dynamic range methods |
| EP2466310A1 (en) | 2010-12-17 | 2012-06-20 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH | Means and methods for detecting double-strand breaks |
| DE102010056289A1 (de) | 2010-12-24 | 2012-06-28 | Geneart Ag | Verfahren zur Herstellung von Leseraster-korrekten Fragment-Bibliotheken |
| GB201101621D0 (en) | 2011-01-31 | 2011-03-16 | Olink Ab | Method and product |
| JP5948673B2 (ja) | 2011-03-10 | 2016-07-06 | ジーンフロンティア株式会社 | リポ多糖混入量を低減した蛋白質合成用組成物、該組成物を用いた蛋白質製造方法 |
| GB201107863D0 (en) | 2011-05-11 | 2011-06-22 | Olink Ab | Method and product |
| WO2012161227A1 (ja) | 2011-05-23 | 2012-11-29 | 独立行政法人理化学研究所 | 核酸構築物、核酸－蛋白質複合体、及びその利用 |
| EP2721152B1 (en) | 2011-06-15 | 2019-03-27 | Navigo Proteins GmbH | Dimeric binding proteins based on modified ubiquitins |
| GB201201547D0 (en) | 2012-01-30 | 2012-03-14 | Olink Ab | Method and product |
| US10421958B2 (en) | 2014-02-05 | 2019-09-24 | Molecular Templates, Inc. | Methods of screening, selecting, and identifying cytotoxic recombinant polypeptides based on an interim diminution of ribotoxicity |
| WO2016062989A1 (en) * | 2014-10-22 | 2016-04-28 | Crescendo Biologics Limited | Human vh domain scaffolds |
| JP6738340B2 (ja) | 2015-02-06 | 2020-08-12 | ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ | 新規なｅｇｆｒ結合タンパク質 |
| ES2916101T3 (es) | 2015-07-16 | 2022-06-28 | Navigo Proteins Gmbh | Nuevas proteínas de unión a inmunoglobulina y su uso en la purificación por afinidad |
| JP2018520675A (ja) | 2015-07-20 | 2018-08-02 | ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ | ジユビキチン変異タンパク質をベースとした新規結合タンパク質及びその生成方法 |
| MY193806A (en) | 2015-09-24 | 2022-10-27 | Abvitro Llc | Affinity-oligonucleotide conjugates and uses thereof |
| WO2018057051A1 (en) | 2016-09-24 | 2018-03-29 | Abvitro Llc | Affinity-oligonucleotide conjugates and uses thereof |
| JP2019526526A (ja) | 2016-05-04 | 2019-09-19 | ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ | ペプチドリンカーを含む化学的部分の部位特異的カップリングのための標的化合物 |
| DK3497117T5 (da) | 2016-08-11 | 2024-09-02 | Navigo Proteins Gmbh | Nye alkalisk stabile immunglobulin-bindende proteiner |
| EP3706804B1 (en) | 2017-11-07 | 2022-02-23 | Navigo Proteins GmbH | Fusion proteins with specificity for ed-b and long serum half-life for diagnosis or treatment of cancer |
| WO2021030271A2 (en) | 2019-08-09 | 2021-02-18 | Nutcracker Therapeutics, Inc. | Methods and apparatuses for manufacturing for removing material from a therapeutic composition |
| EP4382534A1 (en) | 2022-12-06 | 2024-06-12 | Biomérieux | Synthetic peptide for use in an immunomolecular assay |
| CN120858284A (zh) | 2023-01-27 | 2025-10-28 | 生物梅里埃公司 | 用于更快生物标志物检测的改良的免疫分子测定 |
| WO2025111396A1 (en) | 2023-11-20 | 2025-05-30 | Alamar Biosciences, Inc. | Molecular barcode set and use thereof in multiplex proximity detection assays |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06178688A (ja) | 1992-12-11 | 1994-06-28 | Mitsui Toatsu Chem Inc | Ｅ型緑膿菌を抗原とするヒト抗体をコードする遺伝子 |
| AU8124694A (en) * | 1993-10-29 | 1995-05-22 | Affymax Technologies N.V. | In vitro peptide and antibody display libraries |
| CA2402452A1 (en) | 2000-03-31 | 2001-10-11 | Cambridge Antibody Technology Limited | Improvements to ribosome display |
-
1998
- 1998-05-28 ES ES98924468T patent/ES2209145T5/es not_active Expired - Lifetime
- 1998-05-28 US US09/424,712 patent/US6620587B1/en not_active Expired - Lifetime
- 1998-05-28 DK DK98924468T patent/DK0985032T4/da active
- 1998-05-28 CA CA2291721A patent/CA2291721C/en not_active Expired - Fee Related
- 1998-05-28 EP EP98924468A patent/EP0985032B2/en not_active Expired - Lifetime
- 1998-05-28 PT PT98924468T patent/PT985032E/pt unknown
- 1998-05-28 DE DE69818458T patent/DE69818458T3/de not_active Expired - Lifetime
- 1998-05-28 AT AT98924468T patent/ATE250668T1/de active
- 1998-05-28 WO PCT/GB1998/001564 patent/WO1998054312A1/en not_active Ceased
- 1998-05-28 JP JP50038699A patent/JP4060892B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2291721A1 (en) | 1998-12-03 |
| AU7666698A (en) | 1998-12-30 |
| JP2002500514A (ja) | 2002-01-08 |
| PT985032E (pt) | 2004-02-27 |
| AU725957B2 (en) | 2000-10-26 |
| DK0985032T3 (da) | 2004-02-02 |
| CA2291721C (en) | 2011-08-09 |
| DE69818458T2 (de) | 2004-07-08 |
| DK0985032T4 (da) | 2009-08-31 |
| DE69818458D1 (de) | 2003-10-30 |
| EP0985032B1 (en) | 2003-09-24 |
| WO1998054312A1 (en) | 1998-12-03 |
| US6620587B1 (en) | 2003-09-16 |
| EP0985032A1 (en) | 2000-03-15 |
| ES2209145T5 (es) | 2009-10-30 |
| ES2209145T3 (es) | 2004-06-16 |
| EP0985032B2 (en) | 2009-06-03 |
| ATE250668T1 (de) | 2003-10-15 |
| DE69818458T3 (de) | 2009-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4060892B2 (ja) | タンパク質のｉｎ ｖｉｔｒｏディスプレイ及び進化のための選択粒子としてのリボソーム複合体 | |
| US5922545A (en) | In vitro peptide and antibody display libraries | |
| US10329555B2 (en) | High throughput generation and affinity maturation of humanized antibody | |
| JP3507073B2 (ja) | 特異的結合対の成員の製造方法 | |
| US20020068276A1 (en) | Methods for selecting functional polypeptides | |
| He et al. | Selection of a human anti-progesterone antibody fragment from a transgenic mouse library by ARM ribosome display | |
| JP7772379B2 (ja) | 抗原特異的結合ポリペプチド遺伝子ディスプレイベクターの構築方法および用途 | |
| US20020076692A1 (en) | Ribosome display | |
| Lamminmäki et al. | Expanding the conformational diversity by random insertions to CDRH2 results in improved anti-estradiol antibodies | |
| WO1995011922A1 (en) | In vitro peptide and antibody display libraries | |
| KR20110076906A (ko) | 개선된 ｒｎａ 디스플레이 방법 | |
| JP2003536048A (ja) | タンパク質の単離および分析 | |
| EP2970952B1 (en) | An integrated system for library construction, affinity binder screening and expression thereof | |
| He et al. | Ribosome display of antibodies: expression, specificity and recovery in a eukaryotic system | |
| Contreras-Martínez et al. | Intracellular ribosome display via SecM translation arrest as a selection for antibodies with enhanced cytosolic stability | |
| EP3526330A1 (en) | Triple vector for expressing antibody molecules in full therapeutic format | |
| AU2003253193B2 (en) | Novel tricistronic vectors and uses therefor | |
| AU725957C (en) | Ribosome complexes as selection particles for in vitro display and evolution of proteins | |
| CN111201239A (zh) | 用于开发特异于表位翻译后修饰状态的抗体的方法和组合物 | |
| US12503693B2 (en) | Integrated system for library construction, affinity binder screening and expression thereof | |
| WO2004087914A1 (ja) | 抗体作製方法 | |
| Deen | Isolation of Human Endoplasmic Reticulum Antibodies Using Phage Display Technology | |
| WO2003097796A2 (en) | T7 bacteriophage display of fabs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050527 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050527 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070710 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071010 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20071127 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20071221 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101228 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101228 Year of fee payment: 3 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101228 Year of fee payment: 3 |
|
| R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101228 Year of fee payment: 3 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101228 Year of fee payment: 3 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101228 Year of fee payment: 3 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111228 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121228 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121228 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131228 Year of fee payment: 6 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |